Table 1.
Descriptive features for the study groups.
| SSL |
WL |
SW |
||||
|---|---|---|---|---|---|---|
| NIA group | IA group | NIA group | IA group | NIA group | IA group | |
| n | 15 | 12 | 11 | 13 | 10 | 13 |
| Gender (% boys) | 52.63 | 50 | 45.45 | 29.41 | 40 | 38.46 |
| Age | 14.76 (0.42) | 14.60 (0.34) | 14.67 (0.53) | 14.39 (0.44) | 14.67 (0.70) | 14.68 (0.61) |
| Anxiety | ||||||
| T1 | 23.68 (17.97) | 20.81 (18.57) | 30.25 (15.87) | 26.29 (19.48) | 37.33 (17.68) | 31.69 (13.46) |
| T2 | 18.16 (16.78) | 29.56 (18.94) | 23.75 (13.18) | 34.88 (21.21) | 26.25 (18.26) | 38.15 (15.98) |
| T3 | 14.27 (13.88) | 18.29 (18.14) | 25.36 (14.29) | 28.79 (21.92) | 25.30 (20.22) | 35.54 (17.09) |
Note. Mean and standard deviations (between brackets) displayed for numerical data, and percentage of cases for gender.
SSL = Treatment group; WL = Waiting-list group; SW = Placebo group; NIA group = Non-increasing anxiety group; IA group = Increasing anxiety group. Anxiety was measured by the RCADS total anxiety scale (measured in 6-month intervals from T1 to T3).